Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Abroad (travel likely)RecruitingPHASE1

Conditions

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Recurrent Grade 1 Follicular Lymphoma · Recurrent Grade 2 Follicular Lymphoma · Recurrent Grade 3a Follicular Lymphoma · Recurrent Mantle Cell Lymphoma · Recurrent Nodal Marginal Zone Lymphoma · Recurrent Splenic Marginal Zone Lymphoma · Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · Refractory Diffuse Large B-Cell Lymphoma · Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Refractory Grade 1 Follicular Lymphoma · Refractory Grade 2 Follicular Lymphoma · Refractory Grade 3a Follicular Lymphoma · Refractory Mantle Cell Lymphoma · Refractory Nodal Marginal Zone Lymphoma · Refractory Splenic Marginal Zone Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

City of Hope Medical Center, Duarte, California, United States
Contact: Study coordinator (Geoffrey Shouse) · gshouse@coh.org · 626-239-5289
Contact: Principal Investigator (Geoffrey Shouse)

Study leads

Geoffrey Shouse
Principal Investigator
City of Hope Medical Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

B-cell Malignancy · Marginal Zone Lymphoma · Follicular Lymphoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Birmingham, United States · Phoenix, United States

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Mantle Cell Lymphoma · Follicular Lymphoma · Splenic Marginal Zone Lymphoma

Abroad (travel likely)RecruitingPHASE1

Chapel Hill, United States

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

B-Cell Non-Hodgkin Lymphoma · Recurrent Chronic Lymphocytic Leukemia · Recurrent Diffuse Large B-Cell Lymphoma

Abroad (travel likely)RecruitingPHASE1

Jacksonville, United States

Long-term Follow-up Study of Patients Receiving CAR-T Cells

Chronic Lymphocytic Leukemia · Lymphomas Non-Hodgkin's B-Cell · Lymphoma, Small Lymphocytic

Abroad (travel likely)Recruiting

Milwaukee, United States